Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag002 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Joshua N Monteith und 8 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute. Hauptthemen laut MEDLINE: Antibodies, Bacterial, Pseudomonas Infections, Pseudomonas aeruginosa, Cystic Fibrosis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Background
People with cystic fibrosis (pwCF) are susceptible to chronic lung infections, particularly with Pseudomonas aeruginosa. During infection, a subset of patients develops cloaking antibodies specific to O-antigen lipopolysaccharide that impair complement-mediated bactericidal killing. These antibodies associate with worse disease, and their removal via plasmapheresis has been used as a successful treatment for multidrug-resistant P aeruginosa. Whether a similar mechanism of antibody-mediated serum resistance exists toward common polysaccharide antigen (CPA) lipopolysaccharide is unknown.
Methods
Forty-two serum samples and 63 matched P aeruginosa isolates were collected from pwCF. The titers of antibodies specific to CPA in patient sera were determined, and the ability of these antibodies to inhibit serum-mediated killing of P aeruginosa was assessed.
Results
Despite widespread anti-CPA antibodies, only 1 serum-strain pair showed evidence of complement inhibition. Patient serum IgG and IgA responses to CPA were elevated in 86% and 69% of sera, respectively. Furthermore, 69% of pwCF were colonized with CPA-expressing isolates. Despite the high prevalence of elevated anti-CPA antibodies, only 1 patient had antibodies capable of inhibiting complement killing of the cognate P aeruginosa. This isolate, CFP3A, had significantly higher expression of CPA than all other strains. Complement-mediated killing toward it was inhibited by anti-CPA antibodies in a titer-dependent manner.
Conclusions
This investigation reveals that although antibody specific for CPA is prevalent in pwCF, it cannot inhibit complement killing of the majority of CPA-expressing strains. Thus, when Pseudomonas is treated by removal of cloaking antibodies, it is unlikely that CPA-specific antibodies will also need to be eliminated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frazer Institute.
- Institute of Molecular Biology, The University of Queensland, Brisbane, Australia.
- Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
- The Adult Cystic Fibrosis Centre and Department of Thoracic Medicine.
- Queensalnd Lung Transplant Program, The Prince Charles Hospital, Brisbane, Australia.
- School of Medicine.
ORCID-Profile: Emma L Ledger, Michelle N Chamoun, Ian R Henderson, Joanna B Goldberg, Daniel Smith, Simon H Apte, Timothy J Wells
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Monteith, J. N., Ledger, E. L., Chamoun, M. N., Henderson, I. R., Goldberg, J. B., Smith, D., Chambers, D. C., Apte, S. H., & Wells, T. J. (2026). Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag002
Vancouver
Monteith JN, Ledger EL, Chamoun MN, Henderson IR, Goldberg JB, Smith D, et al. Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag002
BibTeX
@article{Monteith2026,
author = {Monteith, Joshua N and Ledger, Emma L and Chamoun, Michelle N and Henderson, Ian R and Goldberg, Joanna B and Smith, Daniel and Chambers, Daniel C and Apte, Simon H and Wells, Timothy J},
title = {Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag002}
}
EUVIMED